Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The CD-19 Antibody Market?

Recent years have seen a robust growth in the size of the CD-19 antibody market. The market, which will expand from $1.75 billion in 2024 to $1.89 billion in 2025, is anticipated to have a compound annual growth rate of 8.3%. The growth during the historical period is linked to factors such as the rising incidence of B-cell malignancies, the advent of immunotherapy, an escalation in funding for oncology research, the emergence of CAR-T cell therapies, increasing awareness about healthcare, and the growing field of personalized medicine.

The market for CD-19 antibodies is predicted to experience significant expansion in the coming years, with its value expected to reach “$2.64 billion by 2029”, witnessing a compound annual growth rate of 8.6%. This growth during the projected period can be due to factors including an increasing demand for cancer treatments aimed specifically at tumours, a surge in the acceptance of smart cell therapies, a growing incidence of blood cancer, extended accessibility to health care services in developing markets, and the advancement of next-generation immune therapies coupled with enhancement in bio-manufacturing technologies. The forecast period will also likely showcase trends such as progress in antibody-drug combinations, the evolution of bispecific antibodies, incorporation of AI into antibody design, advancements in cell-cell therapy platforms, the implementation of single-use bioreactors, the appearance of therapeutic treatments based on nanobodies, and the automation in the manufacturing of biological products.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

Which Key Factors Are Fueling Growth In The CD-19 Antibody Market?

The CD-19 antibody market is anticipated to experience robust growth due to the increasing incidences of B-cell malignancies. B-cell malignancies comprise a variety of cancers that originate from irregular B lymphocytes and includes illnesses like B-cell lymphomas and leukemias. These conditions impact the immune system and can result in unchecked cell growth. The escalating occurrence of B-cell malignancies is connected to multiple factors such as an aging population, genetic predispositions, environmental exposure, lifestyle choices, improved diagnostics, and alterations in the immune system. The CD19 antibody is utilized to treat B-cell malignancies by selectively targeting the CD19 protein found on the surface of the malignant B cells. This specific targeting results in the eradication of these cells while preserving the healthy cells and bolstering the body’s immune defenses. For example, the American Cancer Society, a US-based non-profit organization, reported that 80,620 individuals in the USA were expected to be diagnosed with non-Hodgkin lymphoma in January 2024, and 20,240 individuals, including 44,590 males and 36,030 females, were projected to succumb to non-Hodgkin lymphoma. Thus, the increasing incidences of B-cell malignancies are fuelling the expansion of the CD-19 antibody market.

How Does The CD-19 Antibody Market Differ By Segment?

The cd-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

What New Opportunities Are Emerging From Trends In The CD-19 Antibody Market?

Leading firms in the CD-19 antibody market are directing their efforts towards technological advancements, such as genetically engineered autologous T-cell immunotherapy, to improve the effectiveness of cancer therapies, especially in terms of hematologic malignancies. The described therapy involves genetically modifying a patient’s own T cells to identify and combat cancer cells, these are then reintroduced to the patient’s body to boost the immune response against the disease. An example of this is Autolus Therapeutics plc, a biopharmaceutical firm based in the US, which announced in November 2024 that it had received U.S. FDA approval for AUCATZYL (obecabtagene autoleucel). This is used for the treatment of adult patients suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This method is designed to curtail excess T-cell activation, thus reducing toxicity and improving the longevity of the therapeutic cells. The treatment is administered in split-dose infusion on the first and tenth days, with dosage determined through a bone marrow assessment prior to treatment.

Who Are The Primary Market Leaders In The CD-19 Antibody Market?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

Which Region Is Likely To Register The Fastest Growth In The CD-19 Antibody Market?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model